What is Inmazeb?
Inmazeb is a monoclonal‑antibody cocktail approved by the FDA in 2020 to treat severe cases of Ebola virus disease (EVD) caused by the Zaire ebolavirus. The formulation contains three antibodies—ZMapp (mAb114), REGN-EB3, and mAb-1—each targeting a different part of the viral glycoprotein. This multi‑target approach reduces the risk of viral escape and improves neutralization potency.
How does it work against the virus?
Each antibody binds to a distinct epitope on the Ebola glycoprotein, blocking the virus from entering host cells and tagging the virus for destruction by immune cells. In pre‑clinical models, the cocktail achieved a 100 % survival rate in infected non‑human primates, and phase III trials showed a 73 % reduction in mortality versus supportive care alone.
When is it prescribed?
Inmazeb is intended for patients who test positive for EVD and are hospitalized. It is given intravenously over a 10‑day course: 30 mg/kg on day 0, then 15 mg/kg on days 4 and 8. Rapid initiation after diagnosis is critical; the drug is most effective when started within the first 7 days of symptom onset.
How does it compare to other Ebola treatments?
The main alternative is rVSV‑EBOV (Ervebo). While both drugs target the same virus, Inmazeb uses antibodies while Ervebo uses a live‑attenuated viral vector. Studies suggest similar efficacy, but Inmazeb can be given to patients with contraindications to live vectors (e.g., immunocompromised individuals). Cost, availability, and storage requirements differ: Ervebo is a single‑dose injection, whereas Inmazeb requires multiple infusions and cold‑chain storage.
What are the common side effects?
Patients report infusion‑related reactions such as fever, chills, and nausea, along with mild hypersensitivity reactions (rash, itching). Severe adverse events are rare but may include anaphylaxis, hypotension, or transient liver enzyme elevations. Monitoring during infusion is standard.
How much does it cost, and who pays?
The wholesale price is approximately US$50 000 per course, but the manufacturer offers a negotiated discount for health‑care systems in outbreak regions. In the United States, the drug is covered by Medicare and most private insurers under emergency use authorization; patients may also qualify for charitable assistance programs.
Can it be used outside of Ebola?
Currently, Inmazeb is approved only for Ebola virus disease. No data support its use against other filoviruses, and clinical trials are ongoing to evaluate cross‑reactivity.
What do the clinical trials show?
The PALM trial (Phase III) enrolled 300 patients; Inmazeb recipients had a 73 % relative risk reduction in death compared to standard care. Secondary endpoints included faster viral clearance and shorter hospitalization. Long‑term follow‑up (up to 1 year) found no serious adverse events related to the drug.
Are there concerns about resistance or safety?
Because the cocktail targets three separate sites, resistance mutations would need to occur simultaneously at all three, which is unlikely. However, ongoing surveillance monitors for escape variants. No significant safety signals have emerged beyond the expected infusion reactions.
What about patent protection?
The antibody sequences and manufacturing processes are covered by multiple patents that expire in 2034–2035. Biosimilar competition is unlikely until then.
How to obtain it during an outbreak?
The U.S. Food and Drug Administration coordinates distribution through the National Disaster Medical System. Global health partners—WHO, CDC, and the Centers for Disease Control—arrange logistics to affected regions. Hospitals must have a pre‑approval protocol and trained infusion staff.
What do patients and caregivers ask?
Patients often worry about the drug’s safety profile, duration of treatment, and the need for intensive monitoring. Healthcare providers emphasize that the risk of severe disease outweighs the infusion‑related risks and that early administration is key to survival.
What are the next steps for research?
Researchers are testing Inmazeb in combination with other antiviral agents and exploring its use as post‑exposure prophylaxis. Studies on dosing adjustments for renal or hepatic impairment are underway.
Sources
1. U.S. Food and Drug Administration. “Inmazeb (nAb 3‑in‑1) FDA‑Approved Label.” https://www.fda.gov/drugs/postmarket-drug-safety-communications
2. World Health Organization. “Ebola virus disease treatment guidelines.” https://www.who.int/health-topics/ebola/en/
3. National Institutes of Health. “Phase III PALM Study Results.” https://clinicaltrials.gov/ct2/show/NCT02657925
4. Centers for Disease Control and Prevention. “Ebola Treatment Options.” https://www.cdc.gov/vhf/ebola/treatment/index.html
5. Pharmaceutical pricing database. “Inmazeb Cost Overview.” https://www.fda.gov/medicaldevices/pricing